Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11183259 | 0.85 | ACHE (0.76) | ACHEAKR1B1MEN1GAAKMT2A | |
| SCHEMBL2593829 | 0.84 | ACHE (1.00) | ACHEHDAC1HDAC6AKR1B1 | |
| SCHEMBL11186197 | 0.84 | ACHE (0.74) | ACHEHDAC1HDAC6AKR1B1MEN1 | |
| SCHEMBL8359258 | 0.83 | ACHE (0.71) | ACHEHDAC1HDAC6AKR1B1 | |
| SCHEMBL7137972 | 0.82 | ACHE (0.70) | ACHEHDAC1HDAC6AKR1B1MEN1 | |
| SCHEMBL631839 | 0.82 | ACHE (0.70) | ACHESIGMAR1 | |
| SCHEMBL30945657 | 0.82 | ACHE (0.70) | ACHESIGMAR1 | |
| SCHEMBL4892784 | 0.81 | ACHE (0.80) | ACHEHDAC1HDAC6AKR1B1MEN1 | |
| SCHEMBL60976 | 0.81 | AKR1B1 (0.74) | ACHEHDAC1HDAC6AKR1B1 | |
| SCHEMBL11208411 | 0.81 | ACHE (1.00) | ACHEHDAC1HDAC6AKR1B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2420235-A1 | Methods and combination therapies for treating alzheimer's disease | Medivation Neurology, Inc. (US) | 2012-02-22 | — | — | EP | claimed |
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | MEDIVATION NEUROLOGY, INC. (US) | 2010-06-17 | — | — | US | claimed |
| US-20100152225-A1 | HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME | MEDIVATION NEUROLOGY, INC. | 2010-06-17 | — | — | US | claimed |
| US-20100099700-A1 | HYDROGENATED PYRIDO (4,3-B) INDOLES FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | MEDIVATION NEUROLOGY, INC. | 2010-04-22 | — | — | US | claimed |
| EP-2086538-A2 | COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING I.A. DIMEBON AND DOLEPEZIL | Medivation Neurology, Inc. (US) | 2009-08-12 | — | — | EP | claimed |
| EP-2066322-A2 | HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME | Medivation Neurology, Inc. (US) | 2009-06-10 | — | — | EP | claimed |
| EP-2063892-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | Medivation Neurology, Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2009039420-A9 | METHODS AND COMPOSITIONS FOR TREATING NEURONAL DEATH MEDIATED OCULAR DISEASES | MEDIVATION NEUROLOGY INC (US) | 2009-05-07 | — | — | WO | claimed |
| WO-2009039420-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURONAL DEATH MEDIATED OCULAR DISEASES | MEDIVATION NEUROLOGY, INC. (US) | 2009-03-26 | — | — | WO | claimed |
| EP-1976518-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | Medivation Neurology, Inc. (US) | 2008-10-08 | — | — | EP | claimed |
| WO-2008036400-A2 | HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME | MEDIVATION NEUROLOGY, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| US-20070225316-A1 | Methods and compositions for treating schizophrenia | MEDIVATION, INC. | 2007-09-27 | — | — | US | claimed |
| WO-2007087425-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | MEDIVATION NEUROLOGY,INC. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20070179174-A1 | Methods and compositions for slowing aging | MEDIVATION, INC. | 2007-08-02 | — | — | US | claimed |
| US-20070117835-A1 | Methods and compositions for treating Huntington's disease | MEDIVATION NEUROLOGY, INC. | 2007-05-24 | — | — | US | claimed |
| US-20070117834-A1 | Methods and compositions for treating Huntington's disease | MEDIVATION NEUROLOGY, INC. | 2007-05-24 | — | — | US | claimed |
| WO-2007041697-A2 | HYDROGENATED PYRIDO-INDOLE COMPOUNDS FOR THE TREATMENT OF HUNTINGTON ' S DISEASE | MEDIVATION, INC. (GB) | 2007-04-12 | — | — | WO | claimed |
| EP-1692131-A2 | METHODS AND COMPOSITIONS FOR SLOWING AGING | MEDIVATION, INC. (US) | 2006-08-23 | — | — | EP | claimed |
| WO-2005055951-A2 | METHODS AND COMPOSITIONS FOR SLOWING AGING | MEDIVATION, INC. (US) | 2005-06-23 | — | — | WO | claimed |
| EP-0876818-B1 | AGENT FOR TREATING NEURO-DEGENERATIVE DISORDERS | SELENA PHARMACEUTICALS INC (US) | 2002-12-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152108-A1 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE | PSEN2, APP, PSEN1 | ACHE 12/4885HDAC1 406/4885HDAC6 190/4885 |
| US-20070225316-A1 | Methods and compositions for treating schizophrenia | SLC6A3, DBH, GRIN3B | ACHE 393/4885HDAC1 726/4885HDAC6 607/4885 |
| US-20070179174-A1 | Methods and compositions for slowing aging | PRDX5, HMOX1, SHMT2 | ACHE 398/4885HDAC1 1790/4885HDAC6 855/4885 |
| US-20070117835-A1 | Methods and compositions for treating Huntington's disease | HTT, HYPK, HTR6 | ACHE 171/4885HDAC1 208/4885HDAC6 23/4885 |
| US-20100152225-A1 | HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME | HPD, KYNU, IDO1 | ACHE 1153/4885HDAC1 1640/4885HDAC6 1023/4885 |
| US-20100099700-A1 | HYDROGENATED PYRIDO (4,3-B) INDOLES FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | HTT, NLN, SMN1; SMN2 | ACHE 164/4885HDAC1 1533/4885HDAC6 435/4885 |
| US-20070117834-A1 | Methods and compositions for treating Huntington's disease | HTT, HYPK, HTR6 | ACHE 171/4885HDAC1 208/4885HDAC6 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.